Adding ACEI to Chemotherapy Does Not Prevent Cardiotoxicity.

A new randomized trial presented at the American College of Cardiology (ACC) Scientific Session 2024 showed that adding an angiotensin-converting enzyme (ACE) inhibitor to chemotherapy did not decrease the risk of chemotherapy-related cardiac damage in patients with breast cancer and non-Hodgkin lymphoma. The study included 111 adult patients being treated for breast cancer or NHL with high-dose anthracycline-based chemotherapy. The primary outcome, myocardial injury, measured by high sensitivity cardiac troponin T (cTnT), did not show a statistically significant difference between the group receiving the ACE inhibitor and the standard care group. The study suggests that ACE inhibitors should not be used as a preventative strategy for cardiac damage in these patients. [Extracted from the article]